

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number
WO 2005/092920 A1

(51) International Patent Classification⁷: C07K 14/435, C12N 15/12

Joon [KR/KR]; 4-1202, Faculty Apt., Jigok-dong, Nam-ku, Pohang-city, Kyung-sangbuk-do 790-751 (KR). HWANG, Dong Soo [KR/KR]; 1045-9 Ochi-dong, Buk-gu, Gwangju-city 500-130 (KR).

(21) International Application Number: PCT/KR2005/000888

(74) Agent: YOU ME Patent & Law Firm; Seolim Bldg., 649-10, Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).

(22) International Filing Date: 25 March 2005 (25.03.2005)

(25) Filing Language: Korean

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data: 60/556,805 26 March 2004 (26.03.2004) US

(71) Applicants (for all designated States except US): POSTECH Foundation [KR/KR]; San 31, Hyoja-dong, Nam-ku, Pohang-city, Kyung-sangbuk-do 790-784 (KR). POSCO [KR/KR]; 1, Goedong-dong, Nam-ku, Pohang-shi, Kyung-sangbuk-do 790-300 (KR).

(72) Inventors; and

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),


(75) Inventors/Applicants (for US only): CHA, Hyung

[Continued on next page]

(54) Title: MUSSEL BIOADHESIVE



(A)



(B)



(57) Abstract: The present invention relates to a bioadhesive derived from mussel. In particular, it relates to a novel Mytilus galloprovincialis foot protein type 5 (MGFP-5) and a recombinant protein that is a hybrid of MGFP-5 and foot protein type 1 (FP-1), where an adhesive protein with adhesive activity can be economically mass-produced to be used in place of chemical adhesives through the present invention.

WO 2005/092920 A1



European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

MUSSEL BIOADHESIVE

BACKGROUND OF THE INVENTION

[FIELD OF THE INVENTION]

5 The present invention relates to a bio-adhesive derived from mussel, and more particularly to a novel *Mytilus galloprovincialis* foot protein-5 (MGFP-5) and a recombinant protein that is a hybrid of MGFP-5 and foot protein-1(FP-1).

[BACKGROUND OF THE INVENTION]

 Mussels produce and secrete specialized water-resistant bioadhesives, and
10 have been studied as a potential source of water-resistant bioadhesives. They adhere tightly to surfaces underwater using the byssus secreted from the foot of the mussel. At the end of each thread is an adhesive plaque containing a water-resistant glue that enables the plaque to anchor to wet solid surfaces (Waite, J. H., *Biology Review*. 58:209-231(1983). This strong and water-insoluble adhesion has attracted interest for
15 potential use in biotechnological applications. Mussel adhesive proteins can also be used as medical adhesives as they are non-toxic to the human body and do not impose immunogenicity (Dove et al., *Journal of American Dental Association*. 112:879 (1986)). Moreover, their biodegradable properties make them environmentally friendly.

20 The byssus can be divided into distal and proximal parts. The proximal part is connected to the stem gland of the mussel foot, while the distal part is connected to the adhesive plaques. The adhesive plaque is composed of five distinct types of proteins: foot protein type 1 (FP-1) to type 5 (FP-5) (Deming, T. J., *Current Opinion*

in *Chemical Biology*. 3:100-105 (1999)).

All of the mussel adhesive proteins contain high ratios of 3,4-dihydroxyphenyl-L-alanine (DOPA), which is derived from hydroxylation of tyrosine residues (Waite, J. H., *Biology Review*. 58:209-231 (1983)). The adhesive
5 proteins closest to the adhesion interface have the highest proportion of DOPA residues (Waite, J. H., *Integr. Comp. Biol.* 42:1172-1180 (2002)). In contrast, mussel adhesive protein analogs lacking DOPA show greatly reduced adhesion abilities (Yu et al., *Journal of American Chemical Society*. 121:5825-5826 (1999)). Indeed, a biochemical study showed that DOPA residues can enable mussel adhesive protein
10 molecules to cross-link with each other via oxidative conversion to o-quinone. Thus, the DOPA content of a mussel adhesive protein appears to be specifically related to its adhesive properties.

Currently Cell-Tak, a naturally extracted mussel adhesive protein product, is commercially available. This adhesive is mainly composed of FP-1 and FP-2 type
15 proteins, with a minor portion of FP-3. However, the natural extraction process is labor-intensive and inefficient, requiring around 10,000 mussels for 1 mg of protein (Morgan, D., *The Scientist*. 4:1-6 (1990)).

Therefore, researchers have sought to produce recombinant mussel adhesive proteins, for example FP-1, in expression systems such as *Escherichia coli*
20 and yeast. However, these previous studies failed to express functional and economical mussel adhesive proteins due to a number of complications, including a highly biased amino acid composition (5 amino acid types comprise ~89% of the total amino acids in FP-1), different codon usage preferences between mussel and

other expression systems (tRNA utilization problems) and low protein yields (US Patent No. 5242808, Filpula et al., *Biotechnol. Prog.* 6:171-177 (1990), Salerno et al., *Applied Microbiology and Biotechnology* 58:209-214 (1993), Kitamura et al., *Journal of Polymer Science Part A: Polymer Chemistry*, 37:729-736 (1999)).

5

SUMMARY OF THE INVENTION

An objective of the present invention is to provide a novel adhesive protein gene from mussel and to overcome the aforementioned problems in the prior art.

Another objective of the present invention is to provide a novel adhesive protein from mussel.

Another objective of the present invention is to provide a method for mass-producing a mussel adhesive protein in a biologically active form.

Another objective of the present invention is to provide a recombinant adhesive protein that is a fusion of two or more adhesive proteins from mussel.

Another objective of the present invention is to provide an adhesive that contains a novel adhesive protein as an active component.

The present invention provides a novel adhesive protein extracted from *Mytilus galloprovincialis* and a polynucleotide encoding the protein. The above adhesive protein preferably comprises the amino acid sequence shown in SEQ ID NO: 6. An example of the above polynucleotide is the nucleotide sequence shown in SEQ ID NO: 5.

The present invention also provides a recombinant adhesive protein where some amino acid sequences from FP-1 is attached to the amino- and/or carboxy-

termini of a mussel adhesive protein, and a polynucleotide encoding the recombinant adhesive protein. An example of the recombinant adhesive protein is an amino acid sequence selected from the group consisting of the amino acid sequence shown in SEQ ID NO: 10, the amino acid sequence shown in SEQ ID NO: 12, the amino acid sequence shown in SEQ ID NO: 14, the amino acid sequence shown in SEQ ID NO: 18, the amino acid sequence shown in SEQ ID NO: 20, and the amino acid sequence shown in SEQ ID NO: 22. An example of the nucleotide sequence encoding the recombinant adhesive protein is the nucleotide sequence shown in SEQ ID NO: 9, the nucleotide sequence shown in SEQ ID NO: 11, the nucleotide sequence shown in SEQ ID NO: 13, the nucleotide sequence shown in SEQ ID NO: 17, the nucleotide sequence shown in SEQ ID NO: 19, and the nucleotide sequence shown in SEQ ID NO: 21.

The present invention also provides a vector which contains operably a nucleotide sequence encoding an adhesive protein.

The present invention also provides a transformant which contains operably a nucleotide sequence encoding an adhesive protein.

The present invention also provides a method of producing an adhesive protein which comprises the steps of:

- (a) constructing a vector which contains operably a nucleotide sequence encoding an adhesive protein;
- (b) constructing a transformant by transforming a host cell with the vector; and
- (c) producing a recombinant adhesive protein by culturing the

transformant.

The present invention also provides a method of purifying an adhesive protein which comprises the steps of:

- 5 (a) lysing the transformants, and then centrifuging it to separate the supernatant and the pellet;
- (b) making a suspension by adding an acidic organic solvent to the pellet; and
- (c) centrifuging the suspension to separate the supernatant.

10 The present invention also provides an adhesive containing an adhesive protein as the active component.

The present invention also provides a method of adjusting the adhesive property of an adhesive comprising controlling the concentration of an adhesive protein which is an active component of the aforementioned adhesive, or treating the adhesive with one or more material selected from the group consisting of oxidant,
15 filler and surfactant.

The present invention also provides a coating material containing an adhesive protein as an active component.

BRIEF DESCRIPTION OF THE DRAWINGS

20 Fig. 1 is a picture of the electrophoresis of MGFP-5 cDNA fragments obtained by RT-PCR with RNA extracted from *Mytilus galloprovincialis* as the template.

Fig. 2 shows the procedure for inserting MGFP-5 cDNA into a pTrcHis

vector to construct a pMDG05 vector.

Fig. 3 shows the FP-1 variant (referred to as “6xAKPSYPPTYK” from hereon) where the peptide AKPSYPPTYK is tandemly attached 6 times, and the 4 oligomers KD-1, KD-2, KD-3, and KD-4 that were used in its synthesis.

5 Fig. 4 shows vector diagrams of various combinations that can simultaneously express the 6xAKPSYPPTYK and the MGFP-5 gene.

Fig. 5 is a diagram showing the procedure for constructing the pMDG051 vector for making the recombinant MGFP-51 nucleotide sequence.

10 Fig. 6 is a diagram showing the procedure for constructing the pMDG150 vector for making the recombinant MGFP-15 nucleotide sequence.

Fig. 7 is a diagram showing the procedure for constructing the pMDG151 vector for making the recombinant MGFP-151 nucleotide sequence.

Fig. 8 is a diagram showing the procedure for constructing the pENG151 vector for making the recombinant MGFP-151 nucleotide sequence.

15 Fig. 9 is a photograph of the electrophoresis of each culture material of *E. coli* BL21/pMDG05 and *E. coli* BL21/pTrcHis (*E. coli* BL21/pTrcHisA transformed with pTrcHisA)

Fig. 10 is a Western blot photograph of an SDS-PAGE of the whole cell pellet (WC), soluble upper fraction (I), and insoluble cell debris fraction (IS) isolated from *E. coli* BL21/pMDG05 culture solution, and negative control (N).

20 Fig. 11 is a photograph of silver-stained SDS-PAGE of affinity chromatography fractions for purification of recombinant MGFP-5 protein from *E. coli* BL21/pMDG05.

Fig. 12 is a mass spectrometry result of purified recombinant MGFP-5 protein.

Fig. 13 shows (A) Coomassie blue-stained SDS-PAGE and (B) Western blot analyses of recombinant MGFP-51 protein from *E. coli* BL21/pMDG051.

5 Fig. 14 shows (A) SDS-PAGE and (B) Western blot analyses of recombinant MGFP-15 protein from *E. coli* BL21/pMDG150.

Fig. 15 shows (A) SDS-PAGE and (B) Western blot analyses of recombinant MGFP-151 protein from *E. coli* BL21/pMDG151.

10 Fig. 16 shows the recovery rates of recombinant MGFP-151 protein expressed from *E. coli* BL21/pMDG151 according to the concentration of acetic acid solution.

Fig. 17 shows (A) SDS-PAGE and (B) Western blot analyses of chromatographic fractions of recombinant MGFP-151 protein.

15 Fig. 18 shows the results of coating slide glass, poly(methyl methacrylate) plate, and aluminum plate with recombinant MGFP-5 and recombinant MGFP-151 proteins after the tyrosine residues are modified to DOPA.

Fig. 19 shows the QCM analysis results of BSA, Cell-Tak, recombinant MGFP-5 protein, and recombinant MGFP-151 protein after treating the tyrosines.

20 Fig. 20 is a diagram of the measurement method of the adhesion force of recombinant adhesive proteins.

Fig. 21 shows the adhesion force of recombinant MGFP-1 and recombinant MGFP-5 proteins where the tyrosine residues have been modified.

Fig. 22 is a measurement of cell-adhesion property of recombinant

adhesive proteins.

Fig. 23 is a measurement of cell-adhesion property of recombinant adhesive proteins with insect *Drosophila* S2 cells.

Figs. 24A to C are photographs of a substrate surface coated with recombinant MGFP-5 and recombinant MGFP-151 proteins. A is a 2500X enlargement, B is a 10000x enlargement, and C is a 35000x enlargement.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The inventors of the present invention have obtained a novel adhesion protein and its encoding gene from a type of mussel, *Mytilus galloprovincialis*, and they have established a system for the production of an adhesion protein that is translated from it. They have also established a recombinant adhesion protein that is a fusion of two or more mussel adhesion proteins, and a system for its production.

The adhesive protein of the present invention has the characteristic of attaching to a wide variety of substrates such as glass, metal, polymer resin, plastic or biological cell membranes such as prokaryotic membranes, eukaryotic membranes, and plant cell walls and lipids.

The adhesive protein of the present invention has at least 50 % homology with the amino acid sequence shown in SEQ ID NO: 6, preferably 80 %, more preferably 90 %, and most preferably at least 95 % homology, and at the same time can include amino acid sequences that have adhesive property, for example adhesive property that is similar to the amino acid sequence shown in SEQ ID NO: 6, or amino acid sequences that have 70 to 200 % of the adhesive activity of the above.

For example, there is a protein that contains the amino acid sequence shown in SEQ ID NO: 6. An adhesive protein that contains the amino acid sequence as shown in the above SEQ ID NO: 6 is referred to as "MGFP-5" (*Mytilus galloprovincialis* foot protein type 5) from hereon.

5 A nucleotide encoding MGFP-5 can be expressed as a variety of nucleotide sequences depending on the amino acid codon usage, such as the nucleotide sequences shown in SEQ ID NO: 5 and SEQ ID NO: 15.

Also, the adhesive protein of the present invention can further contain a peptide at the amino- and/or carboxy-termini in order to improve the physicochemical properties of the adhesive protein. The above peptide may be added
10 for the purpose of improving for example, the solubility, adhesion force, degree of crosslinking, and the degree of expression, purification, and recovery of protein. For example, the above peptide can be a general reporter protein such as GST or a histidine tag for the purpose of improving the purification.

15 An example of a form where a peptide is further included for the purpose of purifying an adhesive protein is a protein containing the amino acid sequence shown in SEQ ID NO: 16.

The above peptide preferably contains an amino acid sequence derived from an adhesive protein, and more preferably contains an amino acid sequence
20 derived from a mussel adhesive protein. An example of the peptide is the amino acid sequence shown in SEQ ID NO: 25 is repeated 1 to 10 times in tandem. In an embodiment of the present invention, a SEQ ID NO: 8 was constructed in which the amino acid sequence shown in SEQ ID NO: 25 is repeated 6 times in tandem, and

attached to the amino- and/or carboxy-termini of the adhesive protein in the present invention. The amino acid sequence shown in the SEQ ID NO: 25 is a part of the sequence of the FP-1 protein.

Examples of recombinant adhesive proteins where the sequence shown in
5 SEQ ID NO: 25 is additionally attached, are amino acid sequences shown in SEQ ID
Nos: 10, 12, and 14. The SEQ ID NO: 10 is where the sequence shown in SEQ ID
NO: 25 is repeated 6 times in tandem and attached to the amino-terminus of the
amino acid sequence shown in SEQ ID NO: 6. SEQ ID NO: 12 is where the
sequence shown in SEQ ID NO: 25 is repeated 6 times in tandem and attached to the
10 carboxy-terminus of the amino acid sequence shown in SEQ ID NO: 6. SEQ ID NO:
14 is where the sequence shown in SEQ ID NO: 25 is repeated 6 times in tandem and
attached to the amino- and carboxy-termini of the amino acid sequence shown in
SEQ ID NO: 6.

Furthermore, recombinant adhesive proteins containing the amino acid
15 sequences shown in SEQ ID Nos: 10, 12, or 14 can additionally contain a peptide
which has a purpose of facilitating purification. The peptide may be located on the
amino- and/or the carboxy-termini of a recombinant adhesive protein, and examples
of the peptide are GST and histidine tag. Recombinant adhesive proteins containing
amino acid sequences as shown in SEQ ID Nos: 18, 20, or 22 are forms where a
20 histidine tag is attached to the amino-terminus of a protein containing the amino acid
sequences shown in SEQ ID Nos: 10, 12, or 14 respectively.

The adhesive protein of the present invention can further contain a peptide
of 1 to 10 amino acids that are additionally inserted during cloning of the adhesive

protein, at the amino-terminus, carboxy-terminus, or another kind of connective region of proteins.

The adhesive protein and recombinant adhesive protein of the present invention can be inserted into commonly used expression vectors constructed for
5 expressing exogenous genes, and mass-produced through genetic engineering methods. The above vector may be selected according to the type and characteristics of the host cell used in the production of protein, or it may be newly constructed. Transforming the vector into the host cell and producing the recombinant protein from the transformant can easily be carried out through ordinarily employed methods.
10 Selecting, constructing, transforming the vector and expressing the recombinant protein can be easily carried out by an ordinary person skilled in the art of the present invention, and partial variations in the ordinarily employed methods are also included in the present invention.

The sequence encoding an adhesive protein that is inserted into the vector
15 is a sequence encoding an adhesive protein or a recombinant adhesive protein of the present invention, and is preferably selected from the group consisting of a nucleic acid encoding a protein that has at least 50 % homology, preferably 80 %, more preferably 90 %, and most preferably at least 95 % homology with the amino acid sequence shown in SEQ ID NOs: 6, 10, 12, or 14, a nucleic acid encoding a protein
20 that has at least 50 % homology, preferably 80 %, more preferably 90 %, and most preferably at least 95 % homology with the amino acid sequence shown in SEQ ID NO: 6, 10, 12, or 14, where at least one sequence selected from the group consisting of SEQ ID NO:s 26 to 31 is tandemly repeated 1 to 10 times at the 5' and/or 3' ends

of the nucleic acid, and the amino acid sequence shown in SEQ ID NO: 6, 10, 12, or 14, where 6 histidine residues are additionally attached at the amino-terminus. More preferably, a polynucleotide containing a sequence selected from the group consisting of SEQ ID NOs: 5, 7, 9, 11, 13, 15, 17, 19 and 21 can be inserted into the
5 vector.

In an embodiment of the present invention, MGFP-5 sequence was cloned into a pGEM-T vector, and the sequence shown in SEQ ID NO: 7 (6xAKPSYPPTYK which is 6 tandem repeats of the amino acid sequence shown in SEQ ID NO: 25) was cloned into pUC18. Afterwards, the MGFP-5 sequence was
10 cloned into a pTrcHisA vector to construct a pMDG05 vector (Fig. 4). Furthermore, in order to construct a vector that expresses a recombinant protein having a structure shown in Table 1 below, the sequences of MGFP-5 and SEQ ID NO: 7 were cloned into a pTrcHisA vector to construct pMDG150, pMDG051 and pMDG151 vectors (Fig. 7 to 9).

15 (Table 1)

Hybrid adhesive protein	Structure (5' to 3')	Vector
MGFP-15	6 x AKPSYPPTYK - MGFP-5	pMDG150
MGFP-51	MGFP-5 - 6 x AKPSYPPTYK	pMDG051
MGFP-151	6 x AKPSYPPTYK - MGFP-5 - 6 x AKPSYPPTYK	pMDG151 pENG151

The above pTrcHisA vector is a widely known vector which contains a *trc* promoter, which allows expression of exogenous protein by induction using IPTG(isopropylthio- β -D-galactoside), and which has 6 histidine sequences for
20 protein purification by affinity chromatography at the 5' end of the exogenous gene in order to facilitate protein purification. In the present invention, the pMDG05

vector was deposited at the Korean Collection for Type Cultures (KCTC) at the Biological Resource Center of Korea located at Eouen-dong, Yuseong-gu, Daejeon, Republic of Korea as of June 20, 2002, and received an accession number of KCTC 10291BP. The pENG151 vector was deposited as of January 19, 2005 and given an
5 accession number of KCTC 10766BP.

The expression vector for the adhesive protein and recombinant adhesive protein can be transformed into a host cell selected from the group consisting of prokaryotes, eukaryotes, and eukaryote-derived cells, in order to construct a transformant. The prokaryote is selected from the group consisting of *E. coli* and
10 *Bacillus*, the eukaryote is selected from the group consisting of yeast, insects, animals, and plants, and the eukaryote-derived cells are plant cells, insect cells, and plants, but is not limited thereto.

As an embodiment, pMDG05, pMDG150, pMDG051 and pMDG151 vectors were each transformed into *E. coli BL21*, to construct *E. coli BL21/pMDG05*,
15 *E. coli BL21/pMDG150*, *E. coli BL21/pMDG051* and *E. coli BL21/pMDG151*. The aforementioned 4 types of transformants can be cultured in typical LB media, and IPTG can be added to induce protein expression. The preferred method of expression of recombinant protein is to culture in LB media (5 g/liter yeast extract, 10 g/liter Tryptone, 10 g/liter NaCl), and adding 0.1 to 10 mM of IPTG when the *optical*
20 *density* of the culture solution is 0.6 to 0.9 at 600 nm, then culturing for 2 to 12 hours.

The recombinant protein expressed in the above method is expressed in a water-soluble and/or insoluble form within the transformant, so the isolation and

purification depends on how it is expressed. When it is expressed in a water-soluble form, the recombinant protein can be purified by running the lysed cell supernatant through a chromatography column filled with an affinity resin such as a nickel resin. When it is expressed in a water-insoluble form, the recombinant protein can be purified by suspending the lysed cell pellet in an acidic organic solvent, preferably an organic solvent with a pH of 3 to 6, then centrifuging the suspension to isolate the upper layer. Examples of the acidic organic solvent are acetic acid, citric acid, and lactic acid, but is not limited thereto. The acetic acid used can be 5 to 30 (v/v) %, and preferably the cell pellet is dissolved in 20 to 30 (v/v) % acetic acid solution. The upper layer obtained through treatment with acidic organic solvent can further undergo gel filtration chromatography to further purify the recombinant protein.

Through the method of the present invention, 2-3 mg/L of the recombinant adhesive protein MGFP-5 of at least 95% purity can be obtained, and around 5 mg/L of MGFP-151 of at least 95% purity can be obtained. While MGFP-5 and MGFP-151 display similar levels of adhesion force, the solubility of MGFP-151 is significantly higher compared to MGFP-5, and thus MGFP-151 is easier to obtain in a concentrated form. In particular, MGFP-5 dissolves in a 5 % acetic acid solution to a concentration of around 1 mg/mL, while MGFP-151 dissolves in water to a concentration of around 110 mg/mL, and dissolves in a 5 % acetic acid solution to a concentration of around 220 mg/mL. The solubility of an adhesive protein is directly related to its ability to stay in highly concentrated forms, so the higher the solubility, the easier it is to make highly concentrated forms with high potential for industrial application. In this respect, it can be said that the adhesive protein MGFP-151 is

more useful than MGFP-5.

The adhesive protein and the recombinant adhesive protein obtained through its expression in the present invention have adhesive activity and can be used as adhesives. The adhesive activity was confirmed through the experiment of
5 modifying the tyrosine residues in the protein to 3,4-dihydroxyphenyl-L-alanine (DOPA). Thus, the adhesive protein of the present invention can not only be used as an adhesive for a wide variety of substrates, but also be used as a bioadhesive since it is harmless to the human body.

The present invention also provides an adhesive that contains adhesive
10 protein as an active component. The adhesive protein can be a form where 5 to 100 % of its tyrosine residues are modified to DOPA, and the adhesive can additionally contain a substance that modifies the tyrosine residues in the protein to DOPA. A typical example of the above substance is tyrosinase, but is not limited thereto.

15 The above adhesive can further contain 0.5 to 90 % by weight of an excipient that is generally contained in bioadhesives or is pharmaceutically acceptable. Examples of excipients include surfactants, oxidants, and fillers, but are not limited thereto (see: US Pat. Application Publication No. 2003-65060 and US Pat. No. 5,015,677). The surfactant can be cationic, anionic, non-ionic, or amphoteric,
20 where examples are sodium dodecylsulfate and sodium dodecylbenzenesulfonate. The oxidant can be selected from the group consisting of tyrosinase, catechol oxidase, glutaraldehyde, formaldehyde, bis(sulfosuccinimidyl) suberate, 3,3'-Dithiobis(sulfosuccinimidyl propionate), O₂, Fe³⁺, H₂O₂ and IO₄⁻(see:

Macromolecules 1998, 31, 4739-4745), and the filler can be selected from the group consisting of collagen, hyaluronic acid, chondroitin sulfate, elastine, laminin, caseine, hydroxyapatite, albumin, fibronectin, and hybrin.

The adhesive of the present invention can be used to adhere or fix glass,
5 plastic, polymer resin, or biological specimen, and the detailed mode and amount of usage, formulation and other such matters may follow Cell-Tak (BD Biosciences, Two Oak Park, Bedford, MA, USA) which is currently available commercially. For example, the adhesive of the present invention can be a soluble, water-soluble, or insoluble formulation, and can be used in the amount of 0.01 to 100 ug/cm² for a
10 substrate but is not limited thereto. Furthermore, the mode of use follows the general mode of adhesive use, and the typical mode is coating.

The aforementioned biological specimen refers to any animal or plant categorized as a biological organism and any part derived from such animal or plant. For example, it refers to cells, tissues, organs, RNA, DNA, protein, peptide,
15 polynucleotide, hormones, and compounds, but is not limited thereto.

Examples of application of the adhesive of the present invention are as follows, but not limited thereto: (1) adhesion of substrates under water (fresh or salt water); (2) orthopedic treatments such as treatment of bone, ligament, tendon, meniscus, and muscle, and implant of artificial materials; (3) treatment of
20 perforations, lacerations, and cuts, and ophthalmic attachments such as corneal implants and artificial corneal implants; (4) dental attachments such as holding retainers, bridges, or crowns in place, securing loose teeth, repairing broken teeth, and holding fillers in place; (5) surgical treatments such as attachment of blood

vessels , attachment of cellular tissue, artificial material implants, and closure of wounds; (6) plant attachments such as bonding of transplanted parts and wound healing; (7) drugs, hormones, biological factors, medications, physiological or metabolic monitoring equipment, antibiotics, and cell transplant (see: US 5,015,677).

5 The present invention also provides a method of adjusting the adhesion force of the above adhesive by treating with a substance selected from the group consisting of surfactant, oxidant, and filler, or controlling the concentration of the adhesive protein which is an active component of the adhesive (see: US Pat No.5,015,677). The surfactant, oxidant, and filler are the same as was described
10 above.

 The present invention also provides a coating agent which contains the above adhesive protein as an active component. Since the adhesive protein of the present invention has the characteristic of adhering to glass, plastic, polymer resin, or biological specimen, it can not only be used as a coating agent for these substrates,
15 but also coat the surface of substrates that are used underwater to prevent oxidation of the substrates, since the adhesive protein is water-resistant and water-repellent. An example of application of the coating agent is to coat the motor propeller of ships to prevent corrosion, but is not limited thereto. The above coating agent may consist solely of an adhesion protein, but can additionally contain commonly known
20 adhesives, adhesive proteins other than the adhesive proteins of the present invention, resin contained in commonly known coating agents, organic solvents, surfactants, anticorrosive agents, or pigments. The content of the additional components may be appropriately adjusted within the commonly accepted range depending on the kind of

component and formulation of the coating agent. Where an additional component is included, the adhesive protein as an active component is contained in the coating agent at a level that maintains the adhesive activity, and can for example be contained in the coating agent at 0.1 to 80 % by weight.

5 The coating agent of the present invention can be manufactured in the form of cream, aerosol (spray), solid, liquid, or emulsion, but is not limited to these formulations.

 Embodiments of the present invention are described below. The following embodiments are merely illustrative of the present invention and the present
10 invention is not limited to the following embodiments.

 In the following, the mussel used for cloning the MGFP-5 gene was *Mytilus galloprovincialis*.

Example 1: Cloning of the MGFP-5 gene

15 In order to clone MGFP-5, the primer shown in SEQ ID NO: 1 (5'-ggcctgcagcagttctgaagaatacaaggg-3') and the primer shown in SEQ ID NO: 2 (gtagatctatacgcggaccagtgaacag) were each synthesized. PCR was run 30 times using the mussel cDNA library, and a PCR product of 243 bp was obtained (Fig. 1). The above PCR product was cloned in a pGEM-T vector (Promega).

20 To obtain the upstream signal sequence of MGFP-5, nested PCR was executed using mussel (*M. galloprovincialis*) cDNA library. The primers used were a T3 promoter primer of the ZAP vector (SEQ ID NO: 32) and the primer shown in SEQ ID NO: 3 (5'-cttgatatttcgctgtttt-3'). An amplification product of around 300 bp

was obtained through the PCR and it was cloned into a pGEM-T vector.

To obtain the C-terminal poly-A tail region of MGFP-5, nested PCR was performed using SEQ ID NO: 4 (5'-aaaaacagcggaaaatacaag-3') and T7 promoter primer (SEQ ID NO: 33). The amplification product of 350 bp was obtained and
5 cloned into a pGEM-T vector.

The MGFP-5 cDNA nucleotide sequence obtained from the above was analyzed, and the MGFP-5 nucleotide sequence excluding the secretion signal sequence is shown in SEQ ID NO: 5, and the amino acid sequence encoded therein is shown in SEQ ID NO: 6.

10

Example 2: Construction of the vector for genetically engineered production of MGFP-5

The MGFP-5 cDNA in the pGEM-T vector was isolated by using the restriction enzyme sites *Pst*I and *Eco*RI, then inserted into a pTrcHis A vector
15 (Invitrogen, USA) that was cleaved with *Pst*I and *Eco*RI restriction enzymes to construct pMDG05(4630bp). The pMDG05 vector was deposited at the Korean Collection for Type Cultures (KCTC) at the Biological Resource Center of Korea located at Eoeun-dong, Yuseong-gu, Daejeon, Republic of Korea as of June 20, 2002, and received a accession number of KCTC 10291BP.

20 The pMDG05 vector contains a *trc* promoter for expression in *E. coli*, and allows induction of expression using IPTG (Sigma, USA). It also has 6 histidine residues at the 5' end of the MGFP-5 gene for protein isolation and purification by affinity chromatography.

Example 3: Construction of the peptide (6xAKPSYPPTYK) derived from FP-1

From the amino acid sequence of FP-1 (Genbank No.Q27409 or S23760),
5 an FP-1 derivative as shown in SEQ ID NO: 25 where the peptide “AKPSYPPTYK”
is tandemly repeated 6 times (referred to as “6xAKPSYPPTYK”) was constructed.

That is, KD-1 to KD-4 described in Fig. 3 was each synthesized, and then
annealed, to synthesize 6xAKPSYPPTYK in SEQ ID NO: 8 encoding the FP-1
variant in SEQ ID NO: 7. Additionally, at the 5' end of the 6xAKPSYPPTYK, *EdoRI*
10 and *NheI* restriction enzyme sites in the direction of 5' to 3' were placed, and a
BamHI restriction enzyme site was placed at the 3' end (Fig. 3). The
6xAKPSYPPTYK was inserted into a pUC18 vector using the *NheI* and *BamHI*
restriction enzyme sites to construct the pAD501 vector (M. Kitamura, 1999, Journal
of Polymer Science Part A: Polymer Chemistry 37, 729-736).

15 In Fig. 3, the “ACTAT” located at the 5' side of the *BamHI* site in the
polynucleotide was inserted to preserve the ORF.

Example 4: Construction of recombinant hybrids of FP-1 and MGFP-5

From hereon, MGFP-5 is referred to as “MGFP-5”, a hybrid where
20 6xAKPSYPPTYK of Example 3 is attached to the N-terminus of MGFP-5 is referred
to as “MGFP-15”, a hybrid where 6xAKPSYPPTYK is attached to the C-terminus of
MGFP-5 is referred to as “MGFP-51”, and a hybrid where 6xAKPSYPPTYK is
attached to both the N- and C-termini of MGFP-5 is referred to as “MGFP-151” (see

Table 1 above).

The hybrids MGFP-15 shown in SEQ ID NO: 10, MGFP-51 shown in SEQ ID NO: 12, and MGFP-151 shown in SEQ ID NO: 14 were constructed, and they include histidine tags (6x His) and other amino acid residues at the 5' end and amino acid residues between the 6xAKPSYPPTYK and MGFP-5 due to the design of the experiment.

In order to express each of the hybrids MGFP-5, MGFP-15, MGFP-51 and MGFP-151, the structures shown in SEQ ID Nos: 15, 17, 19, and 21 were inserted into a vector to respectively construct pMDG05, pMDG150, pMDG051, and pMDG151 of Fig. 4. In the above 4 vectors, expression is controlled by a *trc* promoter that is inducible by IPTG (Sigma, US), and there are 6 histidine residues at the 5' region and a translation termination codon (TAA) at the 3' end of each recombinant construct.

The method of construction for each vector is as follows.

PCR was executed on the nucleotide sequence of MGFP-5 within the pMDG05 vector of Example 2 with the primer set shown in SEQ ID NOs: 1 and 2, then cleaved with *Pst*I and *Eco*RI restriction enzymes, then inserted into a pTrcHis A vector (Invitrogen, USA) which was previously cleaved with the same enzymes, to construct pTEMP150(4630bp). Also, the 6xAKPSYPPTYK in the pAD501 vector of Example 2 was amplified with the primer set shown in SEQ ID NO: 23 (5'-GGT ACC CGA ATT CGA ATT CGC TAA ACC G-3') and 24 (5'-GGT CGA CTC AAG CTT ATC ATT TGT AAG TCG-3'), and cleaved with *Eco*RI and *Hind* III restriction enzymes. Then it was inserted into pTEMP150 which was previously cleaved with

EcoRI and *Hind III*, to construct pMDG051 (Fig. 5).

The 6xAKPSYPPTYK in the pAD501 vector was isolated by treating with *Nhe I* and *BamH I* restriction enzymes, and inserted into a pMDG05 vector which was treated with the same enzymes to construct pMDG150 (Fig. 6).

5 The 6xAKPSYPPTYK in the pAD501 vector was isolated by treating with
Nhe I and *BamH I* restriction enzymes, and inserted into a pTrcHis A vector
(Invitrogen, USA) which was treated with the same enzymes, to construct
pTEMP1(4523bp). Then the nucleotide sequence of MGFP-5 within the pMDG05
vector was amplified with the primer set shown in SEQ ID NOs: 1 and 2, then
10 cleaved with *PstI* and *EcoRI* restriction enzymes, then inserted into pTEMP1 which
was treated with the same enzymes, to construct pTEMP2(4741bp). Also, the
6xAKPSYPPTYK in the pAD501 vector was amplified with the primer set shown in
SEQ ID NOs: 23 and 24, then cleaved with *EcoRI* and *Hind III* restriction enzymes.
Then it was inserted into pTEMP2 which was cleaved with *EcoRI* and *Hind III*, to
15 construct pMDG151 (4927bp) (Fig. 7).

Also, in order to express the MGFP-151 nucleotide at a high level, the
MGFP-151 nucleotide was amplified from the pMDG151 vector with the primers
shown in SEQ ID NO: 34 (5'- CCT AAC ATA TGG GGG TTC TCA TCA TC – 3')
and SEQ ID NO: 35 (5'- ATC CGC CAA AAC AGC CAA GCT T – 3'). The
20 amplified product was inserted into a pET 22b(+) vector (Novagen, EMB Bioscience,
Inc. 441 Charmany Dr. Madison, WI 53719 USA) using *Nde I* and *Hind III*
restriction enzymes, to construct a pENG151 vector (Fig. 8). The pENG151 vector
was transformed into *E.coli*, and deposited at the Korean Collection for Type

Cultures (KCTC) at the Biological Resource Center of Korea as of January 19, 2005 and given an accession number of KCTC 10766BP.

Example 5: Construction of transformant producing MGFP-5 and hybrids

5 Competent cells of *E. coli* Top10
 (*F-mcrA(mrr-hsdRMS-mcrBC)Φ80lacZΔM15 ΔlacX74 deoR recA1 araD139*
Δ(ara-leu)7697 galU galK rpsL (Strr) endA1 nup, Invitrogen) used for cloning, and
E. coli BL21 (*F- ompT hsdSB (rB- mB-) gal dc*) used for protein expression were
 each prepared using CaCl₂ buffer. Transformation of each of the pMDG05,
 10 pMDG051, pMDG150 and pMDG151 vectors in Example 4 into the competent cells
 were achieved by a heat shock method (leaving for 2 minutes at 42 °C). Then
 through a selection process using ampicillin (Sigma) the transformants *E. coli*
 Top10/pMDG05, *E. coli* Top10/pMDG051, *E. coli* Top10/pMDG150, *E. coli*
 Top10/pMDG151, *E. coli* BL21/pMDG05, *E. coli* BL21/pMDG051, *E. coli*
 15 BL21/pMDG150 and *E. coli* BL21/pMDG151 were each obtained.

Example 6: Expression and purification of MGFP-5 from *E. coli* BL21/pMDG05

6-1. Culture of *E. coli* BL21/pMDG05

20 *E. coli* BL21/pMDG05 was cultured in LB media (5 g/liter yeast extract,
 10 g/liter Tryptone and 10 g/liter NaCl), and IPTG was added to a final concentration
 of 1 mM when the optical density of the culture solution was 0.7 to 0.8 at 600 nm, to
 induce expression of recombinant adhesive protein MGFP-5. At this time, a culture

solution in 10 mL of LB media (with 500 μg of added ampicillin) cultured for 12 hours in a sterile 50 mL tube was inoculated into 100 mL of LB media contained in a 500 mL flask. The *E. coli* BL21/pMDG05 culture was centrifuged at 18,000 g for 4 to 10 minutes to obtain the cell pellet, and this was stored at -80 °C.

5 6-2. Confirmation of MGFP-5 expression

The cell pellet was resuspended in SDS-PAGE buffer (0.5 M Tris-HCl, pH 6.8, 10 % glycerol, 5 % SDS, 5 % β -mercaptoethanol, 0.25 % bromophenol blue) 100 μl , and denatured by boiling at 100 °C for 5 minutes. For SDS-PAGE analysis, the samples were electrophoresed on a 15% SDS-polyacrylamide gel and then the protein bands detected using Coomassie blue staining (Bio-Rad) or silver staining (Bio-Rad, USA). For Western blot analysis, the samples were electrophoresed on a 15% SDS-polyacrylamide gel and then transferred onto a nitrocellulose membrane at 15 V. The MGFP-5 protein transferred onto the nitrocellulose membrane was detected using a monoclonal anti-histidine ligand antibody (R&D Systems, USA) and a colorimetric reaction.

Fig. 9 is an electrophoretic image of the culture product of *E. coli* BL21/pMDG05 and *E. coli* BL21/pTrcHis (*E. coli* BL21/pTrcHisA transformed with pTrcHisA), where MW is a size marker, N is a control group, and WC is the culture product of *E. coli* BL21/pMDG05. Fig. 9 confirmed the expression of MGFP-5 protein in *E. coli* BL21/pMDG05.

To confirm the expressed form of recombinant MGFP-5 in the cell sample, SDS-PAGE and Western blot was carried out on each of the cell debris and soluble supernatant obtained from lysis of the cell pellet, and the cell pellet.

That is, *E. coli* BL21/pMDG05 cell pellets were resuspended in 5 ml Buffer B (8M urea, 10 mM Tris-Cl, 100 mM sodium phosphate, pH 8.0) per 1 gram cells, and were lysed by gentle shaking for 1 h at room temperature. The lysate was centrifuged at 14,000 rpm for 20 min to obtain the soluble supernatant and insoluble cell debris.

Fig. 10 is a Western blot image of the SDS-PAGE analysis of the cell pellet (WC), soluble supernatant (I), the insoluble cell debris (IS) isolated from the culture solution of *E. coli* BL21/pMDG05 and the negative control (N). Fig. 10 shows that the MGFP-5 protein is detected at high levels in the soluble supernatant fraction, indicating that it is expressed in a soluble form inside the cell.

6-3. Purification of recombinant MGFP-5 protein

In order to isolate and purify recombinant MGFP-5 which is expressed in a soluble form within *E. coli* BL21/pMDG05, affinity chromatography utilizing the histidine affinity ligand contained in the pMDG05 vector was carried out.

Immobilized metal affinity chromatography (IMAC) purification was performed using the Acta Prime Purification System (Amersham Biosciences) at room temperature at a 1 ml per min flow rate. 10 ml Ni-NTA™ Agarose (Qiagen) charged with 0.1 M NiSO₄ (Samchun Chemicals) was used as the resin, and separation was performed under denaturing conditions. After the column was filled with the resin, it was equilibrated with buffer (8M urea, 10 mM Tris-Cl, 100 mM sodium phosphate, pH 8.0). Then the soluble supernatant fraction was loaded onto the column, and then the column was eluted with Buffer A (8M urea, 10 mM Tris-Cl, 100 mM sodium phosphate, pH 6.3) and Buffer B (8M urea, 10 mM Tris-Cl, 100

mM sodium phosphate, pH 5.9). Recombinant MGFP-5 protein was eluted with elution buffer (8M urea, 10 mM Tris-Cl, 100 mM sodium phosphate, pH 4.5), and eluted fractions were all collected and dialyzed in 5% acetic acid at 4 °C (Spectra/Por® molecular porous membrane tubing, Spectrum Laboratories, USA).

5 Fig. 11 is an image of silver-stained SDS-PAGE of affinity chromatography fraction samples during the purification of recombinant MGFP-5 protein from *E. coli* BL21/pMDG05. M is a size marker, Lane 1 is the fraction that was adsorbed when the soluble supernatant fraction was loaded onto the column, Lane 2 is the eluted fraction obtained at the step of washing the column, and Lane 3
10 is the eluted fraction separated by the elution buffer. Fig. 11 shows that the recombinant is purified at a high level of purity.

6-4. Analysis of MGFP-5 recombinant protein

MALDI-TOF (Matrix-assisted laser desorption ionization with
15 time-of-flight) mass spectrometry analysis was performed using a PerSeptive Voyager DE instrument (Perkin-Elmer).

Sinapinic acid in 30 % acetonitrile and 0.1 % trifluoroacetic acid was used as matrix solution. The recombinant MGFP-5 protein obtained from the above section 6-3 was diluted 1:25 with the matrix solution, then 1 µl was spotted onto gold
20 plates and evaporated using a vacuum pump. Mass spectra were acquired in positive ion mode using an accelerating voltage of 25,000 V, grid voltage at 70 to 80 %, guide wire voltage at 0.3 %, delay time of 200 to 500 ns and N₂ laser power at 1600 to 1900 (arbitrary units). Internal calibration was performed using BSA with [M +

H]⁺ at 66.431 and [M + 2H]²⁺ at 33.216.

Fig. 12 is the result of mass spectrometry analysis of MGFP-5 recombinant protein.

5 **Example 7: Expression and purification of MGFP-51 from *E. coli* BL21/pMDG051**

E. coli BL21/pMDG051 was cultured and the cell pellet, cell debris and soluble supernatant fractions were each obtained in the same method as in Example 6. Afterwards, SDS-PAGE and Western blot was carried out on each of the above
10 samples.

Fig. 13 shows photographs of SDS-PAGE analysis (A) and a Western blot analysis (B) of the expression of recombinant MGFP-51 protein from *E. coli* BL21/pMDG051. W is cell pellet, S is soluble supernatant fraction, and IS is insoluble cell debris. Fig. 13 shows that the recombinant MGFP-5 protein is
15 expressed within the cell in both soluble and insoluble forms.

Example 8: Expression and purification of MGFP-15 from *E. coli* BL21/pMDG150

E. coli BL21/pMDG150 was cultured and the cell pellet, cell debris and
20 soluble supernatant fractions were each obtained in the same method as in Example 6. Afterwards, SDS-PAGE and Western blot was carried out on each of the above samples.

Fig. 14 shows photographs of SDS-PAGE analysis (A) and a Western blot

analysis (B) of the expression of recombinant MGFP-15 protein from *E. coli* BL21/pMDG150. M is a size marker, W is cell pellet, S is soluble supernatant fraction, and IS is insoluble cell debris. Fig. 14 shows that the recombinant MGFP-15 protein is expressed within the cell in both soluble and insoluble forms.

5

Example 9: Expression and purification of MGFP-151 from *E. coli* BL21/pMDG151

9-1. Expression of MGFP-151

E. coli BL21/pMDG151 was cultured and the cell pellet, cell debris and soluble supernatant fractions were each obtained in the same method as in Example 6. Afterwards, SDS-PAGE and Western blot was carried out on each of the above samples.

Fig. 15 shows photographs of SDS-PAGE analysis (A) and a Western blot analysis (B) of the expression of MGFP-151 recombinant protein from *E. coli* BL21/pMDG151. W is cell pellet, S is soluble supernatant fraction, and IS is insoluble cell debris. Fig. 15 shows that the MGFP-151 recombinant protein is expressed within the cell in soluble and insoluble forms.

9-2. Purification I of recombinant MGFP-151 protein

Cell pellets were resuspended in 5 ml lysis buffer (10 mM Tris-Cl, 100 mM sodium phosphate, pH 8.0) per gram of cell pellet, then the cells were lysed at 20,000 PSI (Constant systems, Low March, UK). Cell lysates were centrifuged at 18,000 g and 4°C for 20 min to collect the cell debris. The cell debris was resuspended in 20 ml of 5, 10, 15, 20, 25, 30, 22, 24, 26 and 28 (v/v) % acetic acid

solutions per gram cell weight respectively and centrifuged under the same conditions. The supernatant was prepared into a chromatographic sample.

A 40 cm x 2.6 cm column was filled with Sephacryl S-300 HR (Pharmacia), and equilibrated with 5% acetic acid. Afterwards, 2 ml of sample was loaded, and
5 then the sample was eluted with the concentrations of acetic acid that were used to resuspend each sample to collect the eluted fractions. The degree of purification of MGFP-151 in each concentration of acetic acid elution fraction was confirmed by SDS-polyacrylamide gel electrophoresis and then staining by Coomassie blue (Fig. 16). Fig. 16 shows that recombinant MGFP-151 protein is eluted at an acetic acid
10 concentration of 20 to 30 (v/v) %. In particular, it was confirmed that dilution in 25% acetic acid solution showed the best results with 74% purity and 45% yield.

9-3. Purification II of recombinant MGFP-151 protein

Cell pellets were resuspended in 5 ml lysis buffer (10 mM Tris-Cl, 100 mM sodium phosphate, pH 8.0) per gram of cell pellet, then the cells were lysed at
15 20,000 PSI (Constant systems, Low March, UK). Cell lysates were centrifuged at 18,000 g and 4°C for 20 min to collect the cell debris. The cell debris was resuspended in 20 ml of 25 % acetic acid solution per gram cell weight, and centrifuged under the same conditions. After the supernatant was freeze-dried, it was dissolved in 2 ml of 5% acetic acid and prepared into a chromatographic sample.

20 A 40 cm x 2.6 cm column was filled with Sephacryl S-300 HR (Pharmacia), and equilibrated with 5% acetic acid. Afterwards, 2 ml of sample was loaded, and the sample was eluted with 5 (v/v) % acetic acid and eluted fractions I and II were collected. The degree of purification of MGFP-151 in eluted fractions I

and II was confirmed by SDS-polyacrylamide gel electrophoresis and then staining by Coomassie blue (Fig. 17). Fig. 17 shows photographs of SDS-PAGE analysis (A) and a Western blot analysis (B) of the chromatographic fractions of MGFP-151 recombinant protein. recombinant MGFP-151 protein with 95.8% purity could be
5 isolated by chromatography.

The purified recombinant MGFP-151 protein was confirmed to be the same at the initially designed MGFP-151 peptide, through analysis with MALDI-TOF mass spectrometer.

10 **Example 10: Modification of the adhesive protein's tyrosine residues**

The MGFP-5, MGFP-51, MGFP-15 and MGFP-151 adhesive proteins purified in Examples 6 to 9 were each dissolved to a concentration of 1.44 mg/ml in 5% acetic acid buffer containing 25 mM ascorbic acid. Then after the addition of 50 ug/ml of tyrosinase, it was shaken for 6 hours at 25 °C. Through this process, the
15 tyrosine residues of the adhesive proteins were modified to DOPA. Furthermore, bovine serum albumin (BSA) was used as negative control, and the commercial product Cell-Tak™ (BD Bioscience, Two Oak Park, Belford, MA, USA) which consists of mussel adhesive proteins FP-1 and FP-2 was used as positive control.

20 **Example 11: Verification of the ability of the recombinant MGFP-5 and MGFP-151 proteins to coat various surfaces**

The abilities of recombinant MGFP-5 and MGFP-151 proteins to coat the surfaces of glass slide, poly(methyl methacrylate) plate, and aluminum plate were

measured. Each material surface was cleaned by washing with water several times and drying with nitrogen gas. A 5 μ l drop of 1.44 mg/ml protein solution was spotted onto each surface and kept for 12 h at 25 °C. After drying, each surface was washed thoroughly with double distilled water for 2 h with shaking, and the water remaining
5 on each surface was evaporated with a vacuum pump. After drying, the protein coated on the surface was visualized using Coomassie blue staining. This result is shown in Fig. 18.

Fig. 18 shows the result of coating the surfaces of glass slide, poly(methyl methacrylate) plate, and aluminum plate with recombinant MGFP-5 and MGFP-151
10 proteins after their tyrosine residues are modified to DOPA. The recombinant MGFP-5 and MGFP-151 proteins adhered to glass, poly(methyl methacrylate), and aluminum even before modification of their tyrosine residues, and the adhesion force was found to be much higher when the tyrosine residues are modified to DOPA.

15 **Example 12: Measurement of adsorption of recombinant adhesive protein using QCM(Quartz Crystal Microbalance)**

The quartz crystal used (Seiko EG & G) was a gold-coated AT-cut quartz 5 mm in diameter with a basic resonant frequency of 9 MHz. A 5 μ l drop of a 1.44 mg/ml protein solution (BSA, Cell-Tak, recombinant MGFP-5 protein, and recombinant
20 MGFP-151 protein) was each placed onto the gold surface of the quartz crystal and kept at 25 °C in a constant-temperature water bath for 1 hour. After taking it out of the water bath and drying, the gold surface was rinsed thoroughly in double distilled water for 1 h with shaking and the water remaining on the quartz crystal was

evaporated using a vacuum pump. Dried quartz crystal was connected to an EQCM controller (QCA917; Seiko EG & G) and variations in resonance frequency were measured. Since the resonance frequency of the quartz crystal decreases as a function of increase in the mass adsorbed on its surface (G. Sauerbrey, 1959, Z. Phys, 155, 206), the increase in mass was calculated by Equation 1 (M. Thomson, 1991, Analyst, 116, 881-889) with the value for change in resonance frequency.

(Equation 1)

$$\Delta mass = \frac{-\Delta freq \times A \times \sqrt{\mu_q \times \rho_q}}{2 \times F_q^2}$$

In the above Equation 1, $\Delta mass$ is change in mass, $\Delta freq$ is change in resonance frequency, μ_q is AT-cut quartz crystal constant ($2.947 \times 1.011 \text{ g/cm/sec}^2$), P_q is the quartz crystal density (2.648 g/cm^2), F_q^2 is reference frequency (9.00 MHz), and A is quartz crystal surface area (0.196 cm^2).

Fig. 19 is the result of QCM analysis of BSA, Cell-Tak, recombinant MGFP-5 protein and recombinant MGFP-151 protein where the tyrosines were treated, showing the level of adsorption onto the gold surface as change in frequency. In Fig. 19, recombinant MGFP-151 protein modified with tyrosinase showed the greatest change in frequency, indicating the greatest mass adsorbing to the gold surface of the quartz crystal. Although Cell-Tak™ adsorbed in a greater amount compared to BSA, its adhesion force was much lower compared to that of recombinant MGFP-5 protein. The change in mass of recombinant MGFP-151 protein was 36 %, that of recombinant MGFP-5 protein was 23.2 %, and that of Cell-Tak was 10 % or less.

Example 13: Measurement of adhesion force of recombinant adhesion protein using AFM(atomic force microscopy)

5 The force-distance curve was obtained using AFM (SPA400; Seiko Instruments), and AFM cantilevers were done according to the technique of Ducker et al. (W. Ducker, Nature, 1991, 353, 239-241) (Fig. 20). The cantilevers used for the present experiments were Olympus oxide-sharpened silicon nitrate probes (Veeco & Seiko Instruments) and the spring constant was 0.57 or 11 N/m. A glass
10 bead (Park Science) of 20 μm diameter was attached to the tip of the cantilever using an epoxy resin (Vantico), and kept at room temperature for 24 h. The AFM cantilevers with glass bead attached were mounted into the AFM, and the glass bead was immersed in 10 μl of tyrosinase-treated protein solutions (1.44 mg/ml BSA, Cell-Tak™, MGFP-1 or MGFP-5) (MGFP-5 or MGFP-151) for 10 min. The
15 glass bead was brought into contact with clean glass surface, and a force-distance curve was obtained.(Time required for one cycle of the force-distance curve measurement was 5 s. 삽입)

Fig. 21 shows the adhesion force of recombinant MGFP-151 and MGFP-5 proteins with modified tyrosines. Recombinant mussel adhesive proteins MGFP-5
20 and MGFP-151 have average values of 540 nN and 500 nN respectively indicating strong adhesion force, whereas that of Cell-Tak was 250 nN, and that of BSA was around 30 nN. This result shows that tyrosinase-treated recombinant mussel adhesion proteins have strong adhesion ability.

Example 14: Measurement of cell adhesion property

Drosophila S2 cells (Invitrogen) were used.

S2 cells were grown at 27 °C in M3 medium (Shields and Sang M3 insect
5 medium; Sigma, St. Louis, MO) containing 10% IMS (insect medium supplement),
1% antibiotic-antimycotic (Invitrogen), and hygromycin 3 µl/ml. Tyrosinase-treated
recombinant MGFP-5 protein, recombinant MGFP-151 protein, Cell-Tak, and BSA
prepared from Example 10 were dropped onto sterilized slide glass (20 mm x 20 mm,
Marienfeld, Germany) and incubated at 25°C for 30 minutes in a laminar flow hood
10 and then washed two times with PBS. After washing, the coated slide glass was
immersed in 100-mm cell culture dishes containing S2 cells at a concentration of
4×10⁶ cells/ml showing 95% viability. After incubation at 27°C for 1 hr to 7 days,
unattached cells were rinsed away with PBS, and cell viability and location of
adhered protein was checked by trypan blue staining.

15 As a result, S2 cells were found to attach to regions where recombinant
MGFP-5 and MGFP-151 proteins were coated, and the attached S2 cells survived for
7 days or more (Figs. 22 and 23).

**Example 15: Examination of the chemical adhesive stability of MGFP-5
20 and MGFP-151**

The recombinant proteins MGFP-5 and MGFP-151 were each spotted onto
glass and Cell-Tak was spotted on as control. After drying, it was immersed in a
solution consisting of 5 % acetic acid, 25 % methanol, and 70% water, and heated for

20 minutes at 85 °C. As a result, for the adhesive proteins coated on the surface of glass or acrylic plates, it was found that upon leaving at high temperatures under solvent conditions MGFP-5 became detached while MGFP-151 continued to stay attached.

5 Also, each was coated onto glass or acrylic plates and adhesive stability was measured through SEM.

 Figs. 24A to C are photographs of the substrate surfaces coated with recombinant MGFP-5 and MGFP-151 proteins, where A is a 2500X enlargement, B is a 10000x enlargement, and C is a 35000X enlargement. On observation, the
10 surface coated with MGFP-151 was found to be smooth, whereas the surface coated with MGFP-5 was found to be a little bit rough. This difference is thought to be a difference in the degree of cross-linking.

【Sequence list pretext】

15 SEQ ID NOs: 1 to 4 are primer sequences.

 SEQ ID NO: 5 is the cDNA of MGFP-5 protein isolated from *Mytilus galloprovincialis*.

 SEQ ID NO: 6 is the protein sequence of MGFP-5 protein isolated from *Mytilus galloprovincialis*.

20 SEQ ID NO: 7 is the nucleotide sequence of 6 tandem repeats of a partial sequence of MEFP-5 protein isolated from *Mytilus edulis*.

 SEQ ID NO: 8 is the amino acid sequence of 6 tandem repeats of a partial sequence of MEFP-5 protein isolated from *Mytilus edulis*.

SEQ ID NO: 9 is the nucleotide sequence encoding the recombinant adhesive protein MGFP-15 constructed from FP-1 and MGFP-5.

SEQ ID NO: 10 is the amino acid sequence of the recombinant adhesive protein MGFP-15 constructed from FP-1 and MGFP-5.

5 SEQ ID NO: 11 is the nucleotide sequence encoding the recombinant adhesive protein MGFP-015 constructed from FP-1 and MGFP-5.

SEQ ID NO: 12 is the amino acid sequence of the recombinant adhesive protein MGFP-015 constructed from FP-1 and MGFP-5.

10 SEQ ID NO: 13 is the nucleotide sequence encoding the recombinant adhesive protein MGFP-151 constructed from FP-1 and MGFP-5.

SEQ ID NO: 14 is the amino acid sequence of the recombinant adhesive protein MGFP-151 constructed from FP-1 and MGFP-5.

SEQ ID NO: 15 is the nucleotide sequence of the construct inserted into the pMDG05 vector for the expression of MGFP-5.

15 SEQ ID NO: 16 is the amino acid sequence of the adhesive protein expressed from the construct inserted into the pMDG05 vector for the expression of MGFP-5.

SEQ ID NO: 17 is the nucleotide sequence of the construct inserted into the pMDG150 vector for the expression of MGFP-15.

20 SEQ ID NO: 18 is the amino acid sequence of the adhesive protein expressed from the construct inserted into the pMDG150 vector for the expression of MGFP-15.

SEQ ID NO: 19 is the nucleotide sequence of the construct inserted into the

pMDG051 vector for the expression of MGFP-51.

SEQ ID NO: 20 is the amino acid sequence of the adhesive protein expressed from the construct inserted into the pMDG051 vector for the expression of MGFP-51.

5 SEQ ID NO: 21 is the nucleotide sequence of the construct inserted into the pMDG151 vector for the expression of MGFP-151.

SEQ ID NO: 22 is the amino acid sequence of the adhesive protein expressed from the construct inserted into the pMDG151 vector for the expression of MGFP-151.

10 SEQ ID Nos: 23 to 24 are primer sequences.

SEQ ID NO: 25 is a partial sequence of FP-1.

SEQ ID Nos: 26 to 31 are nucleotide sequences encoding AKPSYPPTYK which is a partial sequence of FP-1.

SEQ ID NO: 32 is the primer sequence of the T3 promoter.


15 SEQ ID NO: 33 is the primer sequence of the T7 promoter.

SEQ ID Nos: 34 to 35 are primer sequences.

INTERNATIONAL FORM
RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1


TO : CHUNG, Sung-Kee
 Pohang University of Science & Technology,
 #San 31, Hyoja-dong, Nam-gu, Pohang-si, Kyungbuk 790-784,
 Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> Top10/pMDG05 ✓✓	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 10291BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on June 20 2002 .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on _____ and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority of authorized official(s):  BAE, Kyung Sook, Director Date: June 25 2002

INTERNATIONAL FORM
RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

Issued pursuant to Rule 7.1

TO : PARK, Chan-Mo
 Pohang University of Science & Technology,
 #San 31, Hyoja-dong, Nam-gu, Pohang-si, Kyungpook-do 790-784,
 Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> Top10/pENG151	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 10766BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Jan 19 2005 .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on _____ and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____.	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejeon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority of authorized official(s):  PARK, Yong-Ha Director Date: Jan 24 2005

WHAT IS CLAIMED IS:

1. An adhesive protein comprising an amino acid sequence shown in SEQ ID NO: 6.
2. The adhesive protein of Claim 1, wherein the adhesive protein further
5 comprises a peptide for improving a physicochemical property of the adhesive protein which is attached to a carboxy- and/or amino-termini of the protein.
3. The adhesive protein of Claim 2, wherein the physicochemical property is selected from the group consisting of solubility, adhesion force, cross-linking, and improvement in protein expression, purification, and recovery rate.
- 10 4. The adhesive protein of Claim 2, wherein the peptide is derived from an adhesive protein.
5. The adhesive protein of Claim 4, wherein the adhesive protein is derived from a mussel adhesive protein.
6. The adhesive protein of Claim 2, wherein the peptide is an amino acid
15 sequence as shown in SEQ ID NO: 25 tandemly repeated 1 to 10 times.
7. The adhesive protein of Claim 6, wherein the adhesive protein comprises an amino acid sequence selected from the group consisting of an amino acid sequence as shown in SEQ ID NO: 10, an amino acid sequence as shown in SEQ ID NO: 12, and an amino acid sequence as shown in SEQ ID NO: 14.
- 20 8. The adhesive protein of Claim 2, wherein the peptide comprises 6 histidine residues.
9. The adhesive protein of Claim 8, wherein the adhesive protein comprises an amino acid sequence selected from the group consisting of an amino acid

sequence as shown in SEQ ID NO: 16, an amino acid sequence as shown in SEQ ID NO: 18, an amino acid sequence as shown in SEQ ID NO: 20, and an amino acid sequence as shown in SEQ ID NO: 22.

10. A polynucleotide comprising a nucleotide sequence encoding an adhesive protein according to Claim 1.

11. The polynucleotide of Claim 10, wherein the nucleotide sequence encoding the adhesive protein comprises a nucleotide sequence as shown in SEQ ID NO: 5.

12. A polynucleotide comprising a nucleotide sequence encoding the adhesive protein according to Claim 2 wherein a peptide for improving a physicochemical property of the adhesive protein is attached to a carboxy- and/or amino-termini of the adhesive protein consisting of an amino acid sequence as shown in SEQ ID NO: 6.

13. The polynucleotide of Claim 12, wherein the peptide is an amino acid sequence as shown in SEQ ID NO: 25 tandemly repeated 1 to 10 times.

14. The polynucleotide of Claim 13, wherein a nucleotide sequence encoding the peptide is selected from the group consisting of nucleotide sequences shown in SEQ ID Nos: 26 to 31 tandemly repeated 1 to 10 times.

15. The polynucleotide of Claim 13, wherein the polynucleotide is selected from the group consisting of a nucleotide sequence as shown in SEQ ID NO: 9, a nucleotide sequence as shown in SEQ ID NO: 11, and a nucleotide sequence as shown in SEQ ID NO: 13.

16. A polynucleotide comprising a nucleotide sequence encoding the

adhesive protein according to Claim 8.

17. The polynucleotide of Claim 16, wherein the nucleotide sequence encoding the adhesive protein is selected from the group consisting of a nucleotide sequence as shown in SEQ ID NO: 15, a nucleotide sequence as shown in SEQ ID NO: 17, a nucleotide sequence as shown in SEQ ID NO: 19, and a nucleotide sequence as shown in SEQ ID NO: 21.

18. A vector that comprises operably a nucleotide sequence encoding an adhesive protein according to any one of Claims 1 to 9.

19. The vector of Claim 18, wherein the nucleotide sequence encoding the adhesive protein is selected from the group consisting of a nucleotide sequence as shown in SEQ ID NO: 5, a nucleotide sequence as shown in SEQ ID NO: 9, a nucleotide sequence as shown in SEQ ID NO: 11, a nucleotide sequence as shown in SEQ ID NO: 13, a nucleotide sequence as shown in SEQ ID NO: 15, a nucleotide sequence as shown in SEQ ID NO: 17, a nucleotide sequence as shown in SEQ ID NO: 19, and a nucleotide sequence as shown in SEQ ID NO: 21.

20. The vector of Claim 18, wherein the vector is pMDG05 (KCTC 10291BP) or pENG151(KCTC 10766BP).

21. A transformant transformed with the vector according to Claim 18, wherein the transformant is selected from the group consisting of prokaryotes, eukaryotes, and eukaryote-derived cells.

22. The transformant of Claim 21, wherein the prokaryote is *E. coli* or *Bacillus sp.*

23. The transformant of Claim 21, wherein the eukaryote is selected from

the group consisting of yeast, insects, plants, and animals.

24. The transformant of Claim 21, wherein the eukaryote-derived cells are selected from the group consisting of plant cells, insect cells, and mammalian cells.

25. A method of producing an adhesive protein comprising the steps of:

5 (a) constructing a vector that comprises operably a nucleotide encoding the adhesive protein according to Claim 1;

(b) constructing a transformant by transforming the vector into a host cell;
and

(c) producing recombinant adhesive protein by culturing the transformant.

10 26. The method of Claim 25, wherein the adhesive protein further comprises a peptide for improving a physicochemical property of the adhesive protein attached to a carboxy- and/or amino-termini of the protein.

27. The method of Claim 26, wherein the physicochemical property is selected from the group consisting of solubility, adhesion force, cross-linking, and
15 improvement in protein expression, purification, and recovery rate.

28. The method of Claim 26, wherein the peptide is derived from an adhesive protein.

29. The method of Claim 28, wherein the adhesive protein is derived from a mussel adhesive protein.

20 30. The method of Claim 26, wherein the peptide is an amino acid sequence as shown in SEQ ID NO: 25 tandemly repeated 1 to 10 times.

31. The method of Claim 30, wherein the adhesive protein comprises an amino acid sequence selected from the group consisting of an amino acid sequence

as shown in SEQ ID NO: 10, an amino acid sequence as shown in SEQ ID NO: 12, and an amino acid sequence as shown in SEQ ID NO: 14.

32. The method of Claim 26, wherein the peptide consists of 6 histidine residues.

5 33. The method of Claim 32, wherein the adhesive protein comprises an amino acid sequence selected from the group consisting of an amino acid sequence as shown in SEQ ID NO: 16, an amino acid sequence as shown in SEQ ID NO: 18, an amino acid sequence as shown in SEQ ID NO: 20, and an amino acid sequence as shown in SEQ ID NO: 22.

10 34. A method of purifying adhesive protein comprising the steps of:

(a) lysing the transformant according to Claim 21, and then centrifuging it to isolate each of the supernatant and pellet;

(b) making a suspension by adding acidic organic solvent to the pellet and suspending it; and

15 (c) centrifuging the suspension to isolate the supernatant.

35. The method of Claim 34, wherein the acidic organic solvent has a pH of 3 to 6.

36. The method of Claim 34, wherein the acidic organic solvent is one or more selected from the group consisting of acetic acid, citric acid, and lactic acid.

20 37. The method of Claim 36, wherein the acetic acid is a 5 to 30 (v/v) % aqueous solution.

38. The method of Claim 34, wherein gel filtration chromatography is further carried out on the supernatant of step (c).

39. An adhesive comprising an adhesive protein according to any one of Claims 1 to 9 as an active component.

40. The adhesive of Claim 39, wherein 5 % to 100 % of the total number of tyrosine residues in the adhesive protein is modified to
5 3,4-dihydroxyphenyl-L-alanine (DOPA)

41. The adhesive of Claim 39, wherein the adhesive adheres to a substrate selected from the group consisting of plastic, glass, metal, eukaryotic cells, prokaryotic cells, and plant cell walls and lipids.

42. The adhesive of Claim 39, wherein the adhesive is applied to biological
10 sample.

43. The adhesive of Claim 39, wherein the adhesive further comprises one or more material selected from the group consisting of surfactant, oxidant, and filler.

44. The adhesive of Claim 43, wherein the surfactant is sodium dodecylsulfate or sodium dodecylbenzenesulfonate.

15 45. The adhesive of Claim 43, wherein the oxidant is tyrosinase or H₂O₂.

46. The adhesive of Claim 43, wherein the filler is selected from the group consisting of collagen, hyaluronic acid, chondroitin sulfate, elastine, laminin, caseine, hydroxyapatite, and albumin, fibronectin, and hybrin.


47. The adhesive of Claim 39, wherein the adhesive is applied to substrates
20 used in an underwater environment.

48. A method of adjusting the adhesion force of the adhesive according to Claim 39, wherein the method comprises a step of treating with a substance selected from the group consisting of oxidant, filler, and surfactant, or a step of controlling

the concentration of the adhesive protein which is an active component of the adhesive.

49. A coating agent containing an adhesive protein according to any one of Claims 1 to 9 as an active component.

FIG. 1



2/27

FIG. 2




FIG.3






FIG. 4




5/27

FIG. 5




6/27

FIG. 6




7/27

FIG. 7




8/27




9/27

FIG. 8




10/27

FIG. 9



11/27

FIG. 10



12/27

FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17





FIG. 18



20/27

FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23

(A) Mgf_p-151



(B) Mgf_p-5





FIG. 24A

Mgfp-5



2500X

Mgfp-151



2500X


FIG. 24B

Mgfp-5



10000X

Mgfp-151



10000X


FIG. 24C

Mgfp-5



35000X

Mgfp-151



35000X

SEQUENCE LISTING

	<110>	POSCO POSTECH Foundation	
5	<120>	Mussel Bioadhesive	
	<130>	opp20050258kr	
	<150>	US 60/556,805	
10	<151>	2004-03-26	
	<160>	35	
	<170>	KopatentIn 1.71	
15	<210>	1	
	<211>	30	
	<212>	DNA	
	<213>	Artificial Sequence	
20	<220>		
	<223>	primer	
25	<400>	1	
		ggcctgcagc agttctgaag aatacaaggg	30
	<210>	2	
30	<211>	29	
	<212>	DNA	
	<213>	Artificial Sequence	
	<220>		
35	<223>	primer	
	<400>	2	
40		gtagatctat acgccggacc agtgaacag	29
	<210>	3	
	<211>	21	
	<212>	DNA	
45	<213>	Artificial Sequence	
	<220>		
	<223>	primer	
50	<400>	3	
		cttgtatttt ccgctgtttt t	21

<210> 4
 <211> 21
 <212> DNA
 5 <213> Artificial Sequence

 <220>
 <223> primer

 10 <400> 4
 aaaaacagcg gaaaatacaa g 21

 15 <210> 5
 <211> 228
 <212> DNA
 <213> Mytilus galloprovincialis

 20 <220>
 <221> CDS
 <222> (1)..(228)
 <223> Mytilus galloprovincialis foot protein-5 cDNA

 25 <400> 5
 agt tct gaa gaa tac aaa ggt ggt tat tac cca ggc aat act tac cac 48
 Ser Ser Glu Glu Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Thr Tyr His
 1 5 10 15
 30 tat cat tca ggt ggt agt tat cac gga tcc ggc tat cat gga gga tat 96
 Tyr His Ser Gly Gly Ser Tyr His Gly Ser Gly Tyr His Gly Gly Tyr
 20 25 30
 35 aag gga aag tat tac gga aag gca aag aaa tac tat tat aaa tat aaa 144
 Lys Gly Lys Tyr Tyr Gly Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys
 35 40 45
 40 aac agc gga aaa tac aag tat ctg aag aaa gct aga aaa tac cat aga 192
 Asn Ser Gly Lys Tyr Lys Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg
 50 55 60
 aag ggt tac aag aag tat tat gga ggt ggt agc agt 228
 Lys Gly Tyr Lys Lys Tyr Tyr Gly Gly Gly Ser Ser
 45 65 70 75

 <210> 6
 <211> 76
 50 <212> PRT
 <213> Mytilus galloprovincialis

 <400> 6
 Ser Ser Glu Glu Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Thr Tyr His
 55 1 5 10 15

Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr
 35 40 45

5 Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys
 50 55 60

<210> 9
 10 <211> 411
 <212> DNA
 <213> Artificial Sequence

<220>
 15 <223> Bioadhesive protein(mgfp-150) coding sequence

<220>
 <221> CDS
 20 <222> (1)..(411)
 <223> Bioadhesive protein(mgfp-150)

<400> 9
 25 gct aaa ccg tct tac ccg ccg acc tac aaa gca aaa ccc tcg tac cca 48
 Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro
 1 5 10 15

30 ccg act tat aag gct aaa cct agc tat cca cct acg tac aaa gct aaa 96
 Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys
 20 25 30

35 ccg tct tac ccg ccg act tac aaa gca aaa ccg tcc tac cct ccg acc 144
 Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr
 35 40 45

40 tat aag gct aaa ccg agt tac ccc ccg act tac aaa agt tct gaa gaa 192
 Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ser Ser Glu Glu
 50 55 60

45 tac aag ggt ggt tat tac cca ggc aat tcg aac cac tat cat tca ggt 240
 Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly
 65 70 75 80

50 ggt agt tat cac gga tcc ggc tac cat gga gga tat aag gga aag tat 288
 Gly Ser Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr
 85 90 95

55 tac gga aag gca aag aaa tac tat tat aaa tat aaa aac agc gga aaa 336
 Tyr Gly Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys
 100 105 110

60 tac aag tat cta aag aaa gct aga aaa tac cat aga aag ggt tac aag 384
 Tyr Lys Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys
 115 120 125

411

aag tat tat gga ggt agc agt gaa ttc
 Lys Tyr Tyr Gly Gly Ser Ser Glu Phe
 130 135

5

<210> 10
 <211> 137
 <212> PRT
 10 <213> Artificial Sequence

<400> 10
 Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro
 1 5 10 15
 15 Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys
 20 25 30
 20 Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr
 35 40 45
 Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ser Ser Glu Glu
 50 55 60
 25 Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly
 65 70 75 80
 Gly Ser Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr
 85 90 95
 30 Tyr Gly Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys
 100 105 110
 35 Tyr Lys Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys
 115 120 125
 Lys Tyr Tyr Gly Gly Ser Ser Glu Phe
 130 135

40

<210> 11
 <211> 411
 <212> DNA
 <213> Artificial Sequence

45

<220>
 <223> Bioadhesive protein(mgfp-051) coding sequence

50

<220>
 <221> CDS
 <222> (1)..(411)
 <223> Bioadhesive protein(mgfp-051)

55


```

<400> 11
agt tct gaa gaa tac aag ggt ggt tat tac cca ggc aat tcg aac cac      48
Ser Ser Glu Glu Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His
  1          5          10          15

5  tat cat tca ggt ggt agt tat cac gga tcc ggc tac cat gga gga tat      96
   Tyr His Ser Gly Gly Ser Tyr His Gly Ser Gly Tyr His Gly Gly Tyr
                20          25          30

10 aag gga aag tat tac gga aag gca aag aaa tac tat tat aaa tat aaa      144
   Lys Gly Lys Tyr Tyr Gly Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys
                35          40          45

15 aac agc gga aaa tac aag tat cta aag aaa gct aga aaa tac cat aga      192
   Asn Ser Gly Lys Tyr Lys Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg
                50          55          60

20 aag ggt tac aag aag tat tat gga ggt agc agt gaa ttc gct aaa ccg      240
   Lys Gly Tyr Lys Lys Tyr Tyr Gly Gly Ser Ser Glu Phe Ala Lys Pro
   65          70          75          80

   tct tac ccg ccg acc tac aaa gca aaa ccc tcg tac cca ccg act tat      288
   Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr
                85          90          95

25 aag gct aaa cct agc tat cca cct acg tac aaa gct aaa ccg tct tac      336
   Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr
                100          105          110

30 ccg ccg act tac aaa gca aaa ccg tcc tac cct ccg acc tat aag gct      384
   Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala
                115          120          125

35 aaa ccg agt tac ccc ccg act tac aaa      411
   Lys Pro Ser Tyr Pro Pro Thr Tyr Lys
                130          135

40 <210> 12
   <211> 137
   <212> PRT
   <213> Artificial Sequence

   <400> 12
45 Ser Ser Glu Glu Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His
   1          5          10          15

   Tyr His Ser Gly Gly Ser Tyr His Gly Ser Gly Tyr His Gly Gly Tyr
   50          20          25          30

   Lys Gly Lys Tyr Tyr Gly Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys
   55          35          40          45

   Asn Ser Gly Lys Tyr Lys Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg
   60

```

Lys Gly Tyr Lys Lys Tyr Tyr Gly Gly Ser Ser Glu Phe Ala Lys Pro
 65 70 75 80
 5 Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr
 85 90 95
 Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr
 100 105 110
 10 Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala
 115 120 125
 Lys Pro Ser Tyr Pro Pro Thr Tyr Lys
 130 135
 15
 <210> 13
 <211> 591
 20 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Bioadhesive protein(mgfp-151) coding sequence
 25
 <220>
 <221> CDS
 <222> (1)..(591)
 30 <223> Bioadhesive protein(mgfp-151)
 <400> 13
 35 gct aaa ccg tct tac ccg ccg acc tac aaa gca aaa ccc tcg tac cca 48
 Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro
 1 5 10 15
 ccg act tat aag gct aaa cct agc tat cca cct acg tac aaa gct aaa 96
 40 Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys
 20 25 30
 ccg tct tac ccg ccg act tac aaa gca aaa ccg tcc tac cct ccg acc 144
 45 Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr
 35 40 45
 tat aag gct aaa ccg agt tac ccc ccg act tac aaa agt tct gaa gaa 192
 50 Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ser Ser Glu Glu
 50 55 60
 tac aag ggt ggt tat tac cca ggc aat tcg aac cac tat cat tca ggt 240
 50 Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly
 65 70 75 80
 ggt agt tat cac gga tcc ggc tac cat gga gga tat aag gga aag tat 288
 55 Gly Ser Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr

		85		90		95		
		tac gga aag gca aag aaa tac tat tat aaa tat aaa aac agc gga aaa						336
5		Tyr Gly Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys	100	105		110		
		tac aag tat cta aag aaa gct aga aaa tac cat aga aag ggt tac aag						384
10		Tyr Lys Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys	115	120		125		
		aag tat tat gga ggt agc agt gaa ttc gct aaa ccg tct tac ccg ccg						432
		Lys Tyr Tyr Gly Gly Ser Ser Glu Phe Ala Lys Pro Ser Tyr Pro Pro	130	135		140		
15		acc tac aaa gca aaa ccc tcg tac cca ccg act tat aag gct aaa cct						480
		Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro	145	150		155	160	
20		agc tat cca cct acg tac aaa gct aaa ccg tct tac ccg ccg act tac						528
		Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr	165	170		175		
25		aaa gca aaa ccg tcc tac cct ccg acc tat aag gct aaa ccg agt tac						576
		Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr	180	185		190		
30		ccc ccg act tac aaa Pro Pro Thr Tyr Lys	195					591
		<210> 14						
		<211> 197						
		<212> PRT						
35		<213> Artificial Sequence						
		<400> 14						
40		Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro	1	5	10	15		
		Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys	20	25	30			
45		Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr	35	40	45			
		Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ser Ser Glu Glu	50	55	60			
50		Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly	65	70	75	80		
55		Gly Ser Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr	85	90	95			

Tyr Gly Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys
 100 105 110
 5 Tyr Lys Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys
 115 120 125
 Lys Tyr Tyr Gly Gly Ser Ser Glu Phe Ala Lys Pro Ser Tyr Pro Pro
 130 135 140
 10 Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro
 145 150 155 160
 Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr
 165 170 175
 15 Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr
 180 185 190
 20 Pro Pro Thr Tyr Lys
 195
 <210> 15
 <211> 354
 25 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> construct for expression of Bioadhesive protein(mgfp-5) in pMDG05
 30 vector
 <220>
 <221> CDS
 35 <222> (1)..(351)
 <223> Bioadhesive recombinant protein expressed in pMDG05 vector
 <400> 15
 40 atg ggg ggt tct cat cat cat cat cat cat ggt atg gct agc atg act 48
 Met Gly Gly Ser His His His His His His Gly Met Ala Ser Met Thr
 1 5 10 15
 ggt gga cag caa atg ggt cgg act ctg tac gac gat gac gat aag gat 96
 45 Gly Gly Gln Gln Met Gly Arg Thr Leu Tyr Asp Asp Asp Asp Lys Asp
 20 25 30
 cga tgg gga tcc gag ctc gag atc tgc agc agt tct gaa gaa tac aag 144
 50 Arg Trp Gly Ser Glu Leu Glu Ile Cys Ser Ser Ser Glu Glu Tyr Lys
 35 40 45
 ggt ggt tat tac cca ggc aat tcg aac cac tat cat tca ggt ggt agt 192
 55 Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly Gly Ser
 50 55 60

	tat cac gga tcc ggc tac cat gga gga tat aag gga aag tat tac gga	240
	Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr Tyr Gly	
	65 70 75 80	
5	aag gca aag aaa tac tat tat aaa tat aaa aac agc gga aaa tac aag	288
	Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys Tyr Lys	
	85 90 95	
10	tat cta aag aaa gct aga aaa tac cat aga aag ggt tac aag aag tat	336
	Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys Lys Tyr	
	100 105 110	
15	tat gga ggt agc agt taa	354
	Tyr Gly Gly Ser Ser	
	115	
20	<210> 16	
	<211> 117	
	<212> PRT	
	<213> Artificial Sequence	
25	<400> 16	
	Met Gly Gly Ser His His His His His His Gly Met Ala Ser Met Thr	
	1 5 10 15	
	Gly Gly Gln Gln Met Gly Arg Thr Leu Tyr Asp Asp Asp Asp Lys Asp	
	20 25 30	
30	Arg Trp Gly Ser Glu Leu Glu Ile Cys Ser Ser Ser Glu Glu Tyr Lys	
	35 40 45	
35	Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly Gly Ser	
	50 55 60	
	Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr Tyr Gly	
	65 70 75 80	
40	Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys Tyr Lys	
	85 90 95	
	Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys Lys Tyr	
	100 105 110	
45	Tyr Gly Gly Ser Ser	
	115	
50	<210> 17	
	<211> 456	
	<212> DNA	
	<213> Artificial Sequence	
55	<220>	
	<223> construct for expression of Bioadhesive protein(mgfp-150) in	

pMDG150 vector

<220>
 5 <221> CDS
 <222> (1)..(453)
 <223> Bioadhesive recombinant protein expressed in pMDG150 vector

10 <400> 17
 atg ggg ggt tct cat cat cat cat cat cat ggt atg gct agc gct aaa 48
 Met Gly Gly Ser His His His His His His Gly Met Ala Ser Ala Lys
 1 5 10 15

15 ccg tct tac ccg ccg acc tac aaa gca aaa ccc tcg tac cca ccg act 96
 Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr
 20 25 30

20 tat aag gct aaa cct agc tat cca cct acg tac aaa gct aaa ccg tct 144
 Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser
 35 40 45

25 tac ccg ccg act tac aaa gca aaa ccg tcc tac cct ccg acc tat aag 192
 Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys
 50 55 60

30 gct aaa ccg agt tac ccc ccg act tac aaa ggc tgc agt tct gaa gaa 240
 Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Gly Cys Ser Ser Glu Glu
 65 70 75 80

35 tac aag ggt ggt tat tac cca ggc aat tcg aac cac tat cat tca ggt 288
 Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly
 85 90 95

40 ggt agt tat cac gga tcc ggc tac cat gga gga tat aag gga aag tat 336
 Gly Ser Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr
 100 105 110

40 tac gga aag gca aag aaa tac tat tat aaa tat aaa aac agc gga aaa 384
 Tyr Gly Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys
 115 120 125

45 tac aag tat cta aag aaa gct aga aaa tac cat aga aag ggt tac aag 432
 Tyr Lys Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys
 130 135 140

aag tat tat gga ggt agc agt taa 456
 Lys Tyr Tyr Gly Gly Ser Ser
 145 150

50 <210> 18
 <211> 151
 <212> PRT
 55 <213> Artificial Sequence

<400> 18
 Met Gly Gly Ser His His His His His His Gly Met Ala Ser Ala Lys
 1 5 10 15
 5 Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr
 20 25 30
 10 Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser
 35 40 45
 Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys
 50 55 60
 15 Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Gly Cys Ser Ser Glu Glu
 65 70 75 80
 Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly
 85 90 95
 20 Gly Ser Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr
 100 105 110
 Tyr Gly Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys
 115 120 125
 Tyr Lys Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys
 130 135 140
 30 Lys Tyr Tyr Gly Gly Ser Ser
 145 150

<210> 19
 35 <211> 540
 <212> DNA
 <213> Artificial Sequence

<220>
 40 <223> construct for expression of Bioadhesive protein(mgfp-051) in
 pMDG051 vector

<220>
 45 <221> CDS
 <222> (1)..(537)
 <223> Bioadhesive recombinant protein expressed in pMDG051 vector

50 <400> 19
 atg ggg ggt tct cat cat cat cat cat cat ggt atg gct agc atg act 48
 Met Gly Gly Ser His His His His His His Gly Met Ala Ser Met Thr
 1 5 10 15
 55 ggt gga cag caa atg ggt cgg act ctg tac gac gat gac gat aag gat 96

Gly Gly Gln Gln Met Gly Arg Thr Leu Tyr Asp Asp Asp Asp Lys Asp
 20 25 30

5 cga tgg gga tcc gag ctc gag atc tgc agc agt tct gaa gaa tac aag 144
 Arg Trp Gly Ser Glu Leu Glu Ile Cys Ser Ser Ser Glu Glu Tyr Lys
 35 40 45

10 ggt ggt tat tac cca ggc aat tgc aac cac tat cat tca ggt ggt agt 192
 Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly Gly Ser
 50 55 60

15 tat cac gga tcc ggc tac cat gga gga tat aag gga aag tat tac gga 240
 Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr Tyr Gly
 65 70 75 80

aag gca aag aaa tac tat tat aaa tat aaa aac agc gga aaa tac aag 288
 Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys Tyr Lys
 85 90 95

20 tat cta aag aaa gct aga aaa tac cat aga aag ggt tac aag aag tat 336
 Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys Lys Tyr
 100 105 110

25 tat gga ggt agc agt gaa ttc gct aaa ccg tct tac ccg ccg acc tac 384
 Tyr Gly Gly Ser Ser Glu Phe Ala Lys Pro Ser Tyr Pro Pro Thr Tyr
 115 120 125

30 aaa gca aaa ccc tgc tac cca ccg act tat aag gct aaa cct agc tat 432
 Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr
 130 135 140

35 cca cct acg tac aaa gct aaa ccg tct tac ccg ccg act tac aaa gca 480
 Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala
 145 150 155 160

aaa ccg tcc tac cct ccg acc tat aag gct aaa ccg agt tac ccc ccg 528
 Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro
 165 170 175

40 act tac aaa taa 540
 Thr Tyr Lys

45 <210> 20
 <211> 179
 <212> PRT
 <213> Artificial Sequence

50 <400> 20
 Met Gly Gly Ser His His His His His His Gly Met Ala Ser Met Thr
 1 5 10 15

Gly Gly Gln Gln Met Gly Arg Thr Leu Tyr Asp Asp Asp Asp Lys Asp
 20 25 30

55

Arg Trp Gly Ser Glu Leu Glu Ile Cys Ser Ser Ser Glu Glu Tyr Lys
 35 40 45

5 Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly Gly Ser
 50 55 60

Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr Tyr Gly
 65 70 75 80

10 Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys Tyr Lys
 85 90 95

Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys Lys Tyr
 100 105 110

15 Tyr Gly Gly Ser Ser Glu Phe Ala Lys Pro Ser Tyr Pro Pro Thr Tyr
 115 120 125

Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr
 130 135 140

20 Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala
 145 150 155 160

25 Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro
 165 170 175

Thr Tyr Lys

30

<210> 21
 <211> 642
 <212> DNA
 35 <213> Artificial Sequence

<220>
 <223> construct for expression of Bioadhesive protein(mgfp-151) in
 pMDG151 vector

40

<220>
 <221> CDS
 <222> (1)..(639)
 45 <223> Bioadhesive recombinant protein expressed in pMDG151 vector

<400> 21
 atg ggg ggt tct cat cat cat cat cat cat ggt atg gct agc gct aaa 48
 50 Met Gly Gly Ser His His His His His His Gly Met Ala Ser Ala Lys
 1 5 10 15

ccg tct tac ccg ccg acc tac aaa gca aaa ccc tcg tac cca ccg act 96
 55 Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr
 20 25 30

	tat aag gct aaa cct agc tat cca cct acg tac aaa gct aaa ccg tct	144
	Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser	
	35 40 45	
5	tac ccg ccg act tac aaa gca aaa ccg tcc tac cct ccg acc tat aag	192
	Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys	
	50 55 60	
10	gct aaa ccg agt tac ccc ccg act tac aaa ggc tgc agt tct gaa gaa	240
	Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Gly Cys Ser Ser Glu Glu	
	65 70 75 80	
15	tac aag ggt ggt tat tac cca ggc aat tcg aac cac tat cat tca ggt	288
	Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly	
	85 90 95	
20	ggt agt tat cac gga tcc ggc tac cat gga gga tat aag gga aag tat	336
	Gly Ser Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr	
	100 105 110	
25	tac gga aag gca aag aaa tac tat tat aaa tat aaa aac agc gga aaa	384
	Tyr Gly Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys	
	115 120 125	
30	tac aag tat cta aag aaa gct aga aaa tac cat aga aag ggt tac aag	432
	Tyr Lys Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys	
	130 135 140	
35	aag tat tat gga ggt agc agt gaa ttc gct aaa ccg tct tac ccg ccg	480
	Lys Tyr Tyr Gly Gly Ser Ser Glu Phe Ala Lys Pro Ser Tyr Pro Pro	
	145 150 155 160	
40	acc tac aaa gca aaa ccc tcg tac cca ccg act tat aag gct aaa cct	528
	Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro	
	165 170 175	
45	agc tat cca cct acg tac aaa gct aaa ccg tct tac ccg ccg act tac	576
	Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr	
	180 185 190	
50	aaa gca aaa ccg tcc tac cct ccg acc tat aag gct aaa ccg agt tac	624
	Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr	
	195 200 205	
55	ccc ccg act tac aaa t aa	642
	Pro Pro Thr Tyr Lys	
	210	
	<210> 22	
	<211> 213	
	<212> PRT	
	<213> Artificial Sequence	

<400> 22
 Met Gly Gly Ser His His His His His His Gly Met Ala Ser Ala Lys
 1 5 10 15
 5 Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr
 20 25 30
 Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser
 35 40 45
 10 Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys
 50 55 60
 15 Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Gly Cys Ser Ser Glu Glu
 65 70 75 80
 Tyr Lys Gly Gly Tyr Tyr Pro Gly Asn Ser Asn His Tyr His Ser Gly
 85 90 95
 20 Gly Ser Tyr His Gly Ser Gly Tyr His Gly Gly Tyr Lys Gly Lys Tyr
 100 105 110
 Tyr Gly Lys Ala Lys Lys Tyr Tyr Tyr Lys Tyr Lys Asn Ser Gly Lys
 115 120 125
 25 Tyr Lys Tyr Leu Lys Lys Ala Arg Lys Tyr His Arg Lys Gly Tyr Lys
 130 135 140
 30 Lys Tyr Tyr Gly Gly Ser Ser Glu Phe Ala Lys Pro Ser Tyr Pro Pro
 145 150 155 160
 Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro
 165 170 175
 35 Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr
 180 185 190
 40 Lys Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys Ala Lys Pro Ser Tyr
 195 200 205
 Pro Pro Thr Tyr Lys
 210
 45 <210> 23
 <211> 28
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> primer
 <400> 23
 55 ggtaccgga ttcgaattcg ctaaaccg

5 <210> 24
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer
 10

 <400> 24
 ggtcgactca agcttatcat ttgtaagtcg 30

 15
 <210> 25
 <211> 10
 <212> PRT
 <213> mytilus edulis
 20
 <400> 25
 Ala Lys Pro Ser Tyr Pro Pro Thr Tyr Lys
 1 5 10

 25
 <210> 26
 <211> 30
 <212> DNA
 <213> Mytilus edulis
 30
 <400> 26
 gctaaaccgt cttaccgcc gacctacaaa 30

 35
 <210> 27
 <211> 30
 <212> DNA
 <213> Mytilus edulis

 40
 <400> 27
 gcaaaaccct cgtaccacc gacttataag 30

 45
 <210> 28
 <211> 30
 <212> DNA
 <213> Mytilus edulis

 50
 <400> 28
 gctaaaccta gctatccacc tacgtacaaa 30

 55
 <210> 29
 <211> 30
 <212> DNA

<213> Mytilus edulis
 <400> 29
 5 gctaaaccgt cttaccgcc gacttaaaa 30

<210> 30
 <211> 30
 <212> DNA
 10 <213> Mytilus edulis

<400> 30
 15 gcaaaaccgt cctaccctcc gacctataag 30

<210> 31
 <211> 30
 <212> DNA
 20 <213> Mytilus edulis

<400> 31
 gctaaaccga gttaccccc gacttaaaa 30

25 <210> 32
 <211> 20
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> primer

<400> 32
 35 aattaaccct cactaaaggg 20

<210> 33
 <211> 22
 40 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer
 45

<400> 33
 gtaatacgac tcactatagg gc 22

50 <210> 34
 <211> 26
 <212> DNA
 55 <213> Artificial Sequence

<220>
<223> primer

5 <400> 34
cctaacatat gggggttctc atcatc 26

10 <210> 35
<211> 22
<212> DNA
<213> Artificial Sequence

15 <220>
<223> primer

<400> 35
atccgcaaaa acagccaagc tt 22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR2005/000888**A. CLASSIFICATION OF SUBJECT MATTER****IPC7 C07K 14/435, C12N 15/12**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7: C07K, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubMed, NCBI, Delphion, eKIPASS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	NCBI Accession No. AAS00463 (Feb. 01, 2004)	1, 10 2-9, 11-49
A	US 5202236 (Enzon Labs Inc., Apr. 13, 1993), See entire document.	2-9, 11-49
A	JP 8-266281 (Kaiyo Biotechnol Kenkyusho:KK., Oct. 15, 1996), See entire document.	2-9, 11-49
A	Deming, T.J. "Mussel byssus and biomolecular materials" Vol. 3: pages 100-105 (1999), See entire document.	2-9, 11-49

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 JULY 2005 (21.07.2005)

Date of mailing of the international search report

22 JULY 2005 (22.07.2005)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

PARK, JEONG UNG

Telephone No. 82-42-481-8159



INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR2005/000888

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of :

a. type of material

- a sequence listing
 table(s) related to the sequence listing

b. format of material

- in written format
 in computer readable form

c. time of filing/furnishing

- contained in the international application as filed
 filed together with the international application in computer readable form
 furnished subsequently to this Authority for the purposes of search

2. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2005/000888

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5202236	Apr. 13, 1993	EP 0304486 A1 WO 8807076 A1	Mar. 01, 1989 Sep. 22, 1988